KYNTRA BIO, INC. KYNB

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Kyntra Bio, Inc. ("Kyntra Bio" or the "Company") is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.

In January 2026, the Company announced its rebranding from "FibroGen, Inc." to "Kyntra Bio, Inc.", representing the next step of its transformation and focus on oncology and associated rare disease indications. On January 8, 2026, the Company's common stock began trading under the new Nasdaq symbol "KYNB."

We are developing FG-3246, a potential first-in-class antibody-drug conjugate ("ADC") targeting CD46, for the treatment of metastatic castration-resistant prostate cancer ("mCRPC") and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography ("PET") biomarker and imaging agent. We initiated a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC, along with the exploratory sub-study of FG-3180, in the third quarter of 2025.

Last close 4.58 2026-10-23
Market cap $18.5M 2026-06-30 share count
52-week range 4.56 - 9.70

Valuation FY2025 figures against the last close

P/S2.9x
P/E0.1x
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS45.37

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • Europe
  • Japan
  • Other
Revenue by geography, 3 categories over 1 years. The same figures are in the table below. FY2025 Europe, FY2025: 5.6M (87.6%) 88% Europe Japan, FY2025: 797K (12.4%) 12% Japan Other, FY2025: 0 (0.0%)
Region FY2025
Europe $5.6M
Japan $797.0K
Other $0

As the company reported it, from the “Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $6.4M$29.6M$46.8M$140.7M$235.3M$176.3M$256.6M$213.0M$131.0M$183.2M
Cost of revenue $556.0K$15.6M$4.0M$20.3M$12.9M$8.9M$1.1M———
Gross profit $5.9M$14.1M$42.8M$120.5M$222.4M$167.4M$255.4M———
R&D $23.5M$95.7M$266.5M$296.8M$387.0M$252.9M$209.3M$235.8M$196.5M$187.2M
SG&A $27.7M$49.3M$86.5M$124.7M$123.9M$106.4M$135.5M$63.8M$51.8M$46.0M
Total operating expenses $52.3M$180.0M$369.5M$441.8M$523.8M$368.2M$345.9M$299.7M$248.3M$233.2M
Operating income -$45.9M-$150.4M-$322.7M-$301.0M-$288.5M-$191.9M-$89.3M-$86.7M-$117.3M-$50.0M
Interest expense $8.8M$8.2M$8.1M$1.4M$1.1M$2.4M$2.9M$11.0M$9.7M$10.7M
Pre-tax income -$58.3M-$153.4M-$323.2M-$294.9M-$290.7M-$188.7M-$76.6M-$86.1M-$120.6M-$58.1M
Income tax $90.0K$269.0K$252.0K$358.0K$347.0K$360.0K$328.0K$304.0K$321.0K$71.0K
Net income $183.5M-$47.6M-$284.2M-$293.7M-$290.0M-$189.3M-$77.0M-$86.4M-$120.9M-$58.1M
EPS, basic 45.37-11.89-2.92-3.14-3.14-2.11————
EPS, diluted 45.37-11.89-2.92-3.14-3.14-2.11-0.89-1.03-1.66-0.93
Shares, diluted (wtd. avg.) 4.0M4.0M97.3M93.6M92.3M89.9M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $47.9M$50.5M$81.6M$155.7M$171.2M$678.4M$126.3M$89.3M$673.7M$173.8M
Short-term investments $41.1M$0$121.9M$266.3M$234.0M$8.1M$407.5M$532.1M$62.1M$79.4M
Receivables $216.0K$481.0K$5.1M$16.3M$17.4M$41.9M$28.5M$63.7M$8.5M$10.4M
Inventory $3.7M$3.2M$17.2M$40.4M$31.0M$16.5M$6.9M$0——
Total current assets $99.1M$196.5M$331.6M$492.8M$474.1M$755.1M$702.5M$690.0M$749.0M$266.5M
Property, plant and equipment —$0$4.8M$20.6M$28.3M$33.6M$42.7M$127.2M$129.5M$123.7M
Total assets $119.6M$214.5M$423.5M$610.1M$773.8M$826.8M$857.4M$880.6M$898.6M$469.6M
Accounts payable $3.7M$5.1M$15.8M$30.8M$26.1M$24.8M$6.1M$9.1M$5.5M$6.2M
Total current liabilities $29.2M$133.3M$217.7M$273.6M$225.5M$163.2M$102.7M$89.0M$86.0M$65.1M
Long-term debt $75.0M—————————
Total liabilities $115.1M$398.2M$585.7M$611.6M$544.7M$385.4M$322.0M$352.1M$350.9M$294.4M
Retained earnings -$1.71B-$1.89B-$1.84B-$1.56B-$1.26B-$974.0M-$784.7M-$715.8M-$630.7M-$509.8M
Total equity -$30.0M-$225.6M-$183.7M-$1.5M$229.1M$441.4M$535.4M$528.5M$547.7M$135.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$4.8M-$138.0M-$315.0M-$145.9M-$82.2M$81.6M-$78.7M-$76.1M-$66.5M$7.1M
Depreciation and amortisation $713.0K$2.7M$9.5M$10.0M$10.2M$11.7M$11.1M$6.6M$6.1M$6.0M
Stock-based compensation $6.6M$25.2M$50.8M$65.6M$71.2M$72.7M$66.3M$52.1M$37.5M$32.1M
Capital expenditure $38.0K$266.0K$2.5M$3.7M$5.2M$4.0M$5.8M$8.0M$8.5M$1.3M
Investing cash flow $35.4M$126.0M$153.7M$89.1M-$427.0M$452.5M$120.0M-$522.1M$69.9M$6.6M
Financing cash flow -$86.0M-$255.0K$122.7M$46.8M-$563.0K$13.3M-$4.3M$13.9M$496.5M$6.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182044.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M Revenue, FY2016: 183.2M Net income, FY2016: -58.1M Revenue, FY2017: 131M Net income, FY2017: -120.9M Revenue, FY2018: 213M Net income, FY2018: -86.4M Revenue, FY2019: 256.6M Gross profit, FY2019: 255.4M Net income, FY2019: -77M Revenue, FY2020: 176.3M Gross profit, FY2020: 167.4M Net income, FY2020: -189.3M Revenue, FY2021: 235.3M Gross profit, FY2021: 222.4M Net income, FY2021: -290M Revenue, FY2022: 140.7M Gross profit, FY2022: 120.5M Net income, FY2022: -293.7M Revenue, FY2023: 46.8M Gross profit, FY2023: 42.8M Net income, FY2023: -284.2M Revenue, FY2024: 29.6M Gross profit, FY2024: 14.1M Net income, FY2024: -47.6M Revenue, FY2025: 6.4M Gross profit, FY2025: 5.9M Net income, FY2025: 183.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $183.2M $131.0M $213.0M $256.6M $176.3M $235.3M $140.7M $46.8M $29.6M $6.4M
Gross profit — — — $255.4M $167.4M $222.4M $120.5M $42.8M $14.1M $5.9M
Net income -$58.1M -$120.9M -$86.4M -$77.0M -$189.3M -$290.0M -$293.7M -$284.2M -$47.6M $183.5M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%